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Background: The heart relies on continuous energy production and imbalances herein impair cardiac function di-
rectly. The tricarboxylic acid (TCA) cycle is the primary means of energy generation in the healthy myocardium,
but direct noninvasive quantiﬁcation ofmetabolic ﬂuxes is challenging due to the low concentration ofmostme-
tabolites. Hyperpolarized 13C magnetic resonance spectroscopy (MRS) provides the opportunity to measure cel-
lular metabolism in real time in vivo. The aim of this work was to noninvasively measure myocardial TCA cycle
ﬂux (VTCA) in vivo within a single minute.
Methods and results: Hyperpolarized [1-13C]acetate was administered at different concentrations in healthy rats.
13C incorporation into [1-13C]acetylcarnitine and the TCA cycle intermediate [5-13C]citrate was dynamically de-
tected in vivowith a time resolution of 3 s. Different kineticmodelswere established and evaluated to determine
themetabolic ﬂuxes by simultaneously ﬁtting the evolution of the 13C labeling in acetate, acetylcarnitine, and cit-
rate. VTCA was estimated to be 6.7 ± 1.7 μmol · g−1 · min−1 (dry weight), and was best estimated with a model
using only the labeling in citrate and acetylcarnitine, independent of the precursor. The TCA cycle rate was not
linearwith the citrate-to-acetatemetabolite ratio, and could thus not be quantiﬁed using a ratiometric approach.
The 13C signal evolution of citrate, i.e. citrate formationwas independent of the amount of injected acetate, while
the 13C signal evolution of acetylcarnitine revealed a dose dependencywith the injected acetate. The 13C labeling
of citrate did not correlate to that of acetylcarnitine, leading to the hypothesis that acetylcarnitine formation is
not an indication of mitochondrial TCA cycle activity in the heart.
Conclusions: Hyperpolarized [1-13C]acetate is a metabolic probe independent of pyruvate dehydrogenase (PDH)
activity. It allows the direct estimation of VTCA in vivo, which was shown to be neither dependent on the admin-
istered acetate dose nor on the 13C labeling of acetylcarnitine. Dynamic 13C MRS coupled to the injection of
hyperpolarized [1-13C]acetate can enable themeasurement ofmetabolic changes during impaired heart function.© 2015 Elsevier Ltd. All rights reserved.1. Introduction
To ensure contractile performance and support myocardial work-
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r Biomedical Imaging (CIBM),adenosine triphosphate (ATP). A large fraction ofmyocardial ATP is gen-
erated through the tricarboxylic acid (TCA) cycle, the rate of which re-
ﬂects the myocardial oxygen consumption [1]. Since the ﬂux through
the TCA cycle (VTCA) is tightly linked to the mechanical workload of
the heart, variations in VTCA are indicative of impaired myocardial me-
tabolism and function. In the healthy myocardium, fatty acids are the
preferredmetabolic substrates but the propensity of the heart to extract
energy from this type of fuel can be strongly altered in cardiac diseases.
Acetate, although not a physiological substrate for the heart, has been
shown to be a revealing tracer for assessing myocardial oxidative me-
tabolism via positron emission tomography (PET) [2] and 13C magnetic
resonance spectroscopy (MRS) [1,3,4]. It is the shortest fatty acid and its
uptake into the heart occurs through simple diffusion, its exchange be-
tween plasma and tissue only depending on the concentration gradient
[5]. It is an effective oxidizable substrate formed endogenously that can
be activated to acetylCoA via cytosolic or mitochondrial acetylCoA
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present in the liver, while the mitochondrial variant is abundant in the
heart and muscle and provides acetylCoA that is utilized mainly for
oxidation under ketogenic conditions [7]. AcetylCoA enters the tricar-
boxylic acid (TCA) cycle as citrate via an irreversible condensation
with oxaloacetate catalyzed by citrate synthase. Since the inner mito-
chondrial membrane is impermeable to acetylCoA, an excess in
acetylCoA can be transferred to the cytosol via a carnitinemediated ace-
tyltransferase system [8]. The conversion of acetylCoA to acetylcarnitine
is catalyzed by carnitine acetyl transferase (CAT), an enzyme largely
found in heart mitochondria, peroxisomes, the endoplasmic reticular
lumen but not in the cytosol [9,10]. The shuttling of acetylcarnitine
across mitochondrial membranes is an exchange process mediated by
acetylcarnitine translocase (ATL). The reported absence of CAT from
the cytosol, may suggest two metabolic routes of acetate, (i) passing
by the peroxisomal centers to enter themitochondria as acetylcarnitine,
or (ii) a direct entry via mitochondrial ACS. There have been conﬂicting
reports on the involvement of CAT and acetylcarnitine in the transfer of
acetyl groups from peroxisomes to the cytosol as discussed in [11], and
therefore the conversion of acetate to acetylCoA via mitochondrial ACS
seems most likely (Fig. 1).
The dynamic aspect of in vivo 13CMRS followingmetabolic substrate
injection and its large chemical shift range, can provide unique insights
into the metabolic state of the heart [1,12–15]. However, because of
their inherent low concentrations, TCA cycle intermediates cannot
be detected in vivo using thermally polarized 13C-labeled substrates.
Instead, VTCA is estimated from the kinetics of incorporation of 13C la-
bels into glutamate via an isotopic exchange with 2-oxoglutarate
[13,14,16,17]. This indirect assessment not only involves TCA cycle
activity, but also the oxoglutarate–malate carrier, since a large por-
tion of the detected glutamate is located in the cytosol [18,19]. There-
fore, variations observed in the 13C labeling dynamics of glutamate may
indicate perturbations in metabolic intermediate pool size changes or
membrane transport as in the ischemia-reperfusion model, where it
was found that the rate of glutamate labeling decreased while VTCAFig. 1.Diagram of acetate metabolism in the healthymyocardium, depicting the propaga-
tion of the 13C labeling. Upon entering the cardiomyocyte, acetate is transformed to
acetylCoA via acetylCoA synthetase (ACS). Carnitine acetyltransferase (CAT) converts
acetylCoA to acetylcarnitine. Acetylcarnitine translocase (ATL) transports the
acetylcarnitine into the mitochondrion. Citrate synthase (CS), the activity of which deter-
mines the TCA cycle ﬂux, condenses oxaloacetate with acetylCoA to form citrate. The grey
boxes indicate the 13C labeled metabolites which were detected in this study, namely
[1-13C]acetate, [1-13C]acetylcarnitine and [5-13C]citrate.remained normal [20]. The measurement of label incorporation into
TCA cycle intermediates such as citrate, which is predominantly mito-
chondrial, would enable a direct estimation of VTCA.
Hyperpolarization via dissolution dynamic nuclear polarization
(DNP) increases the sensitivity of 13C MRS by several orders of magni-
tude and allows for the detection of less abundant metabolites in vivo
[21]. The technique provides unique insights into important questions
regarding myocardial metabolism, substrate preference, pharmacologi-
cal intervention, and the ability to differentiate between normal and
pathological metabolism [22–33]. Pyruvate is by far the most widely
used hyperpolarized 13C substrate and it can be served as a probe formi-
tochondrial oxidative ﬂux [34]. The entry of the 13C label into the TCA
cycle via acetylCoA is however dependent on the ﬂux through pyruvate
dehydrogenase (PDH), an enzyme that is tightly regulated and will
hinder the direct assessment of VTCA. Unlike pyruvate, acetate uptake
is independent of PDH activity. A study of hyperpolarized [1-13C]acetate
metabolism in resting rat skeletal muscle showed that the rate of
acetylcarnitine 13C labeling can be directly translated to the metabolic
ﬂux through ACS [35]. However, despite the fact that [1-13C]acetylCoA
was detected in the mouse heart and liver following the injection of
hyperpolarized [1-13C]acetate [36], 13C label incorporation from acetate
into myocardial TCA cycle intermediates has to date not been reported
in vivo. This is most likely due to their low concentration combined
with their spectral proximity to the large 13C resonance of the injected
precursor. This is supported by the in vivo data obtained following the
injection of hyperpolarized [1-13C]butyrate in which citrate was clearly
observed [32,37].
The aim of the present studywas to take advantage of the sensitivity
gain provided by hyperpolarization together with an increased
chemical-shift resolution at high ﬁeld to determine, in a single one-
minute 13C MRS experiment, myocardial TCA cycle ﬂux in vivo
using hyperpolarized [1-13C]acetate as a metabolic substrate.2. Methods
2.1. Animals
All animal experiments were conducted according to the Swiss fed-
eral ethical guidelines and were approved by the local regulatory body.
Male Sprague Dawley rats (300 g) were anesthetized with 1.5%
isoﬂurane in oxygen (n = 12). A catheter was placed into the femoral
vein for intravenous delivery of the acetate solution. A second catheter
was placed in the artery to monitor the blood pressure, which was
used as a cardiac triggering signal and for blood sampling. Animals
were placed and immobilized in a homebuilt holder tominimize poten-
tial motion during MRI and MRS acquisitions. Body temperature was
maintained at 37 °C using a warm water circulation system. Arterial
blood pressure, heart rate, and respiratory ratewere continuouslymon-
itored with an animal monitoring system (SA Instruments, NY, USA).
Arterial pH and pressures of O2 and CO2 were measured using a blood
gas analyzer (AVL Compact 3, Diamond Diagnostics, MA, USA). The
rate-pressure-product (RPP) was determined from the arterial blood
pressure and the heart rate. A summary of physiological parameters
can be found in Table 1.Table 1
Summary of physiological parameters (n = 12).
Heart rate (min−1) 367 ± 17
Systolic pressure (mm Hg) 135 ± 28
Diastolic pressure (mm Hg) 101 ± 33
Rate pressure product (mm Hg min−1) 50969 ± 11,811
Respiration rate (min−1) 63 ± 8
pH 7.39 ± 0.02
pCO2 37.5 ± 4.4
pO2 238.7 ± 35.5
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Unless otherwise speciﬁed, all chemicals were purchased from
Sigma-Aldrich (Buchs, Switzerland). Sodium [1-13C]acetate was dis-
solved to a concentration of 4.5 M in a 1:2 mixture of fully deuterated
ethanol (d6-EtOD) and water (D2O) containing 33 mM of TEMPO
(2,2,6,6-tetramethylpiperidine-1-oxyl) free radical. A total volume of
300 μL of this solution was inserted, in the form of 10 μL frozen beads
(prepared in liquid nitrogen), into a 5 T custom-designed DNP polarizer
preﬁlledwith liquid helium [38]. The 13C nucleiwere dynamically polar-
ized for 2 h at 1.15 K. Following a previously described automated pro-
cess [39], the beads were rapidly dissolved in 6 mL of pressurized,
heated D2O and the resulting solution was transferred within 2 s into
a separator/infusion pump located inside an actively shielded 31-cm di-
ameter horizontal bore 9.4 Tmagnet (Magnex Scientiﬁc, Abingdon, UK)
[40]. The separator/infusion pump was preﬁlled with 0.6 mL of phos-
phate buffered saline and heparin. Subsequently, 1.0 mL of solution at
physiological temperature and pH, with a 13C polarization level of
13 ± 2%, was automatically injected into the femoral vein of the anes-
thetized animal in 5 s. To determine the inﬂuence of the administrated
amount of acetate, the 1.0 mL bolus of hyperpolarized [1-13C]acetate
was injected at a dose ranging from 0.3 to 1.0 mmol/kg.2.3. In vivo MRI and MRS
All 13C MRS and 1H magnetic resonance imaging (MRI) measure-
ments were carried out at 9.4 T with a Direct Drive spectrometer
(Agilent, Palo Alto, CA, USA). A home-built 13C/1H probe, consisting
of a pair of 10 mm diameter 13C surface coils in quadrature mode
and a single 10 mm diameter 1H surface coil, was placed over the
rat chest, localizing signal from the cardiac muscle. A hollow glass
sphere with a 3 mm inner diameter (Wilmad-LabGlass, NJ, USA)
was ﬁlled with an aqueous 1 M [1-13C]glucose solution and used to
adjust the radiofrequency (RF) excitation pulse power and set the
reference frequency. Once the animal was positioned inside the
magnet, ten axial 1 mm thick slices were acquired using a non-
triggered gradient echo sequence (repetition time: TR = 50 ms; echo
time: TE = 3 ms; ﬁeld of view: FOV = 30 × 30 mm2; matrix size:
128 × 128; ﬂip angle: θ = 30°; number of averages: NA = 8) from
which the correct position of the animal was determined. This was
followed by the acquisition of cinematographic images (FOV =
40 × 40 mm2; matrix size: 256 × 256; TR = 140 ms; TE = 4.5 ms;
NA = 8; number of frames: 14; slice thickness: 1 mm) to conﬁrm and
set the timing of the cardiac trigger in the end-diastolic phase. The car-
diac triggerwas typically send 50 or 60ms after themaximumobserved
blood pressure. Cardiac triggered and respiratory gated shimming was
performed to reduce the localized proton line width in a myocardial
voxel of 4 × 5 × 5 mm3 to 20–30 Hz using a triggered FASTESTMAP
sequence [41], resulting in a non-localized proton line width of
80–120 Hz. The spectrometer was triggered to start acquisition at the
beginning of the automated injection process. Series of single pulse
acquisitions were sequentially recorded using 30° adiabatic RF exci-
tation pulses (BIR-4) [42], with 1H decoupling using WALTZ [43].
Free induction decays were acquired with 4129 complex data points
over a 20 kHz bandwidth. All acquisitions were cardiac triggered and
respiratory gated, resulting in a nominal TR between 3 and 3.5 s. The
adiabatic pulse offset and power were calibrated to ensure that the
RF excitation angle θ= 30° for all observed metabolites in the entire
tissue of interest. Following in vivo data acquisition, a 200 μL liquid
sample was extracted from the separator/infusion pump to retro-
spectively determine the precise injected [1-13C]acetate concentra-
tion [35]. The blood volume of the animals was obtained using the
relation between total blood volume and body weight published by
Lee and Blaufox [44] allowing calculation of the blood 13C acetate
concentration.2.4. Data analysis
A non-linear least-squares quantiﬁcation algorithm (AMARES) im-
plemented in the jMRUI software package was used to ﬁt the dynamic
13C MRS data [45]. The spectra were corrected for the phase and DC
offset. Soft constraints were imposed to peak frequencies (182.55–
182.65 ppm for acetate, 173.85–173.95 ppm for acetylcarnitine, and
179.65–179.75 ppm for citrate) and line widths (FWHM= 10–30 Hz),
and the relative phases were ﬁxed to zero.
The time courses of the quantiﬁed peak areas were analyzed with
Matlab (TheMathWorks, Natick, MA, USA) using the kinetic models de-
scribed in thenext sections. Correlationmatrices indicative of the extent
to which free parameters affect each other were calculated for all anal-
yses. The signal decay of precursor and metabolites results from a com-
bination of the effects of longitudinal relaxation (characterized by the
time constant T1), RF excitation, and biochemical conversion and all
time courses were corrected for the effect of repeated RF excitations.
The T1 of [1-13C]acetylcarnitine was set to 14.9 s, as previously deter-
mined in vivo [35], and that of [5-13C]citrate to 20 s [46]. The acetate sig-
nal decay was treated as free parameter. The 13C labeling of acetate
entering the myocardium was treated as an instantaneous enrichment
to its maximum value using an exponential function.
2.5. Kinetic model of myocardial acetate metabolism
A kinetic model describing the dynamic 13C labeling pattern follow-
ing the metabolism of [1-13C]acetate (Fig. 1) was implemented. It con-
sists of a system of coupled differential equations that can be depicted
by a box diagram (Fig. 2A) and are described as follows:
d
dt
13ACE ¼−VACS
13ACE
ACE
; ð1Þ
d
dt
13COA ¼ VACS
13ACE
ACE
−VfCAT
13COA
COA
þ VbCAT
13CAR
CAR
−VCS
13COA
COA
; ð2Þ
d
dt
13CAR ¼ VfCAT
13COA
COA
−VbCAT
13CAR
CAR
; ð3Þ
d
dt
13CIT ¼ VCS
13COA
COA
−VTCA
13CIT
CIT
: ð4Þ
ACE, COA, CAR, and CIT represent the total metabolic pool size of ac-
etate, acetylCoA, acetylcarnitine, and citrate, respectively. 13ACE, 13COA,
13CAR, and 13CIT represent the size of the corresponding 13C-labeled
pools. VACS is the ﬂux through ACS, VCATf and VCATb are the forward and
backward ﬂuxes through CAT, respectively, VTCA is the TCA cycle ﬂux,
and VCS the ﬂux through citrate synthase. By substituting the acetylCoA
term (VfCAT
13COA
COA ) in Eq. (3) using Eq. (2) and by using the small pool size
approximation (ddt
13COAbb ddt
13CAR) [35] and the assumption that the
13C fractional enrichment of acetylcarnitine is proportional to the one
of acetylCoA, i.e.
13COA
COA ¼ α
13CAR
CAR , which is supported by the rapid
13C ex-
change between acetylCoA and acetylcarnitine observed by Schroeder
et al. [47], the system simpliﬁes to (Fig. 2B):
d
dt
13ACE ¼−VACS
13ACE
ACE
; ð5Þ
d
dt
13CAR ¼ VACS
13ACE
ACE
−VIM
13CAR
CAR
; ð6Þ
d
dt
13CIT ¼ VIM
13CAR
CAR
−VTCA
13CIT
CIT
; ð7Þ
where the intermediate ﬂux VIM is deﬁned as αVCS. See Supplemental
Methods for a detailed description of the model. The value of α is not
Fig. 2. Box diagrams representing all the compartments and ﬂuxes involved in the metabolic pathway of acetate into the TCA cycle (A). (B,C,D) describe respectively the three different
mathematical models which were used to analyze the dynamic 13C MRS data. Both the acetylcarnitine and citrate resonances originate from the myocardial tissue, therefore models 2
and 3 describe uniquely the myocardial compartments. In model 1, an instantaneous enrichment of acetate was assumed, employing an exponential input function Fi. In models 2 and
3, the input function was described by the 13C labeling time course of acetate and acetylcarnitine respectively.
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60% of pyruvate-derived acetylCoA cycled through the acetylcarnitine
pool before citrate formation [47], the factor α is expected to be at most
1/0.6.
This mathematical model is an extension of the model we have
previously used to analyze hyperpolarized acetate metabolism in
skeletal muscle [35] and in the heart [48]. As for most 13CMRS exper-
iments, the signals originating from different cellular compartments
cannot be separated and the model assumes that all processes take
place within the same cellular compartment. It must however be
borne in mind that the pathways through which citrate and
acetylcarnitine can be 13C-labeled are restricted because of the
short experimental time, and although it is very possible that some
13C-citrate and 13C-acetylcarnitine ﬂow from the mitochondria to
the cytosol, they are labeled while located in the mitochondria. In
other words, the dynamics of 13C incorporation into citrate and
acetylcarnitine is independent of the ﬁnal location of both metabo-
lites as long as the experiment is short enough for not having them
labeled through other pathways, and ultimately the 13C signal that
is measured is a direct readout of the 13C incorporation into mito-
chondrial citrate and acetylcarnitine.
In the heart, the observed acetate signal originates from both tissue
and blood, compartments which cannot be distinguished. Three differ-
ent modeling approaches were investigated (See also Supplemental
Methods): in model 1 (Fig. 2B), the three equations (Eqs. (5)–(7))
are used to ﬁt the signal evolution of acetate, acetylcarnitine, and cit-
rate with a total of 5 free parameters, namely, the decay rate of ace-
tate (R1,ACE1), VACS, VIM, VTCA and the acetate input function Fi. In
model 2 (Fig. 2C), only the time courses of the two downstream me-
tabolites are ﬁtted and the substrate signal is used as an input func-
tion, Fi = 13ACE(t), with VACS, VIM and VTCA as free parameters. In
model 3 (Fig. 2D), the citrate signal evolution is solely ﬁtted andthe acetylcarnitine is taken as an input function, Fi = 13CAR1(t),
with only two free parameters, namely, VIM and VTCA. Themathemat-
ical models were adjusted to the 13C curves by non-linear regression
using the Levenberg–Marquardt algorithm, coupled to a Runge–
Kutta method to obtain numerical solutions of the ordinary differen-
tial equations that deﬁne each model. All numerical procedures were
performed using Matlab. Fitted parameters are reported with stan-
dard deviation.
The concentration of citratewas set to 1.48 μmol/g dryweight, as de-
termined in healthy male Sprague Dawley rats fed ad libitum and
weighing between 300 and 400 g [49], i.e., in animals having precisely
the same speciﬁcations as those used in the present study. Note that
pool sizes might differ in animals with different metabolic states or dis-
ease and should bemodiﬁed accordingly. A wet/dry weight ratio of 5.29
was assumed [50]. The pool sizes of acetate [ACE] and acetylcarnitine
[CAR]were not set but incorporated in the estimated kinetic parameters
of themodel, i.e., kACS=VACS/[ACE] and kIM=VIM/[CAR], due to limited
evidence of the stability of the ACE and CAR pool sizes during the
experiment.
3. Results
The metabolism of acetate was detected in the healthy rat myo-
cardium within the ﬁrst minute after its administration. Following
the injection of the hyperpolarized [1-13C]acetate bolus, both
[1-13C]acetylcarnitine and [5-13C]citrate were rapidly isotopically
enriched and detected in vivo with a time resolution of 3 s
(Fig. 3A). Despite the narrow 13C line widths (20–40 Hz), it was not
possible to detect the [5-13C]citrate resonance in 2 out of the 12 ex-
periments due to the close spectral proximity of the large [1-13C]ac-
etate resonance (Fig. 3B and C). The signal integral of the precursor
and downstream metabolites were plotted as a function of time
Fig. 3. 13CMR spectra acquired after the injection of hyperpolarized [1-13C]acetate (182.6 ppm). (A) Evolution of the spectrum as a function of time; a spectrumwas acquired each 3 swith
a 30° RF excitation angle adiabatic rf pulse; the inset shows the enlarged spectral region between 172 and 175 ppm, containing the resonance of [1-13C]acetylcarnitine (173.9 ppm). (B,C)
Sum of 4 spectra (t = 21 to t = 30 s) revealing more clearly the presence of the TCA cycle intermediate [5-13C]citrate (179.7 ppm).
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ed with sufﬁcient signal-to-noise ratio (SNR), to be signiﬁcantly
above the noise level for 7 out of the 10 experiments in which citrate
was detected (SNR larger or equal to 3 in the absence of line broad-
ening). After reaching a maximum signal integral 8 ± 3 s after the
start of the injection (Fig. 4A), the hyperpolarized [1-13C]acetate sig-
nal decayed mono-exponentially with a time constant of 9.6 ± 1.6 s.
The maximum acetylcarnitine signal integral was recorded 15 ± 3 s
after the beginning of the injection and the maximum citrate signal
integral approximately 6 s later (Fig. 4B).
To determine VTCA, the ACS rate kACS and the intermediate rate kIM
as well as the [1-13C]acetylcarnitine, [5-13C]citrate, and [1-13C]ace-
tate signal time courses were simultaneously ﬁtted to each one of
the three different mathematical models described in the Methods
section. The appropriateness of each model was tested by evaluating
the accuracy of each ﬁt as well as the interdependence of ﬁt param-
eters. The resulting VTCA values ranged from 6.7 ± 1.7 to 16.4 ±
8.7 μmol · g−1 · min−1 dry weight using model 3 and 1, respectively
(Table 2, Fig. 5A). Although these results vary 3-fold, the estimation
of VTCA provided by model 3 was clearly less dependent on other
ﬁtting parameters and therefore more robust (Fig. S1). This model
only ﬁts the dynamics of the formation of citrate while using the
time course of acetylcarnitine as an input function. It is therefore in-
dependent of the infused substrate acetate and leads to a more con-
sistent estimation of VTCA.Fig. 4. Representative dynamic curves of the peak integrals of 13C-labeled acetate (A), acetylcar
the metabolic model. The grey boxes indicate the average time, ±one standard deviation, at wSimilar kACS values were deduced from both models 1 and 2, re-
spectively 1.7 ± 0.4 and 1.8 ± 0.4 ms−1 (Table 2, Fig. 5B), and the
kIM extracted from all three models ranged from 24.7 ± 3.9 to
37.4 ± 14.0ms−1 (Table 2, Fig. 5C). Themean VTCA and kIM values ex-
hibit a clear dependence on the model and their standard deviation
decreases with the number of reduced free parameters (Table 2,
Fig. 5). In addition, the correlation matrices show that when the
number of free parameters decreases, they become less dependent
on one another (Fig. S1). Both these observations support that kIM
and VTCA were best estimated using model 3. It was observed that
neither VTCA nor kIM depends on the amount of injected substrate,
but that kACS decays with increasing acetate dose, displaying a
Michaelis–Menten like trend (Fig. S2A). The acetylcarnitine-to-
acetate ratio showed a similar trend as function of the injected ace-
tate dose (Fig. S2B) and it scaled linearly with kACS (Fig. S3). The
citrate-to-acetate ratio did not correlate with the injected acetate
dose or with any other determined parameter, showing that a
ratiometric approach cannot be used to estimate myocardial VTCA.
4. Discussion
This study reports for the ﬁrst time the direct in vivo detection of a
TCA cycle intermediate following myocardial metabolism of acetate.
Through the time-resolvedmeasurement of 13C citrate, a direct estimate
of the VTCA ﬂux could be determined.nitine and citrate (B) obtained in a single experiment. The dashed line represents the ﬁt to
hich the maximum of the respective resonance was observed across all experiments.
Table 2
Estimatedmetabolic ﬂuxes and rates found using the three described kineticmodels. Data
are given as mean values ± SEM with the corresponding percentage errors in brackets.
The spread as well as the error percentage of the estimated kinetic parameters decreased
with the reduced number of free parameters. According to the calculated correlation ma-
trixes (Fig. S1), model 3 estimates VTCA with the least inﬂuence of the other estimated pa-
rameters. Note that model 3 only incorporates the labeling of myocardial metabolites and
kACS was therefore not determined since the dynamics of the acetate signal was not taken
into account.
Kinetic model
Parameter 1 (n = 7) 2 (n = 7) 3 (n = 7)
VTCA (μmol · g−1 · min−1
dry weight)
16.4 ± 8.7
(53%)
9.0 ± 3.9
(43%)
6.7 ± 1.7
(25%)
kIM (ms−1) 37.4 ± 14.0
(37%)
28.6 ± 7.3
(25%)
24.7 ± 3.9
(16%)
kACS (ms−1) 1.7 ± 0.4
(22%)
1.8 ± 0.4
(20%)
–
134 J.A.M. Bastiaansen et al. / Journal of Molecular and Cellular Cardiology 87 (2015) 129–137As in most hyperpolarized 13C MRS experiments, elevated substrate
concentrations were required. In this study, the estimated maximum
plasma concentration at the end of the bolus injection was between 3
and 15 mM, which immediately decayed after the bolus injection. In
previous metabolic studies, 45 min-long acetate infusions have been
used, leading to plasma concentrations up to 10mM [16,51], and no ad-
verse effects were reported in hyperpolarized MR studies with compa-
rable doses of 13C-acetate [35,36,52–54]. In the present study, all
monitored physiological parameters remained stable before and after
injection (Table 1), and no adverse effects were observed following ac-
etate administration.
In contrast to earlier investigations in cardiac muscle performed
at 2.35 T or 3 T [36,52,54], the increased spectral resolution obtained
at 9.4 T allowed for the direct observation of the [5-13C]citrate reso-
nance, and illustrates the beneﬁt and need for high ﬁeld. The delayed
observation of citrate with respect to acetylcarnitine is consistent
with the role of carnitine as a shuttle for acetyl groups across the mi-
tochondrial membrane, and as a mitochondrial buffer for excessFig. 5.Metabolic ﬂuxes and rates estimated (n=7) using three different kineticmodels of
myocardial acetate metabolism. Error bars indicate ± SEM. As the number of free param-
eters decreases, the standarddeviation of the estimated kinetic parameter kIM and theVTCA
ﬂux decreases as well.acetylCoA. A similar evolution of the 13C labeling of citrate was de-
tected using the hyperpolarized carbohydrate [2-13C]pyruvate [55].
However, in these studies the mitochondrial uptake of pyruvate is
mediated by PDH where acetylcarnitine acts as a buffer for excess
acetylCoA, which was shown to be a rapid exchange process [56].
The acetylCoA resonance previously reported at 202 ppm after a 90°
excitation in the mouse heart following the injection of hyperpolarized
[1-13C]acetate could not be detected in the present study [36]. Detect-
able quantities of 13C-labeled glutamate could be expected since 60%
of the 14C activity measured 2 min after the injection of 14C-labeled ac-
etate was associated with glutamate while a mere 8% was found to
come from TCA cycle metabolites [57]. It was nevertheless not possible
to detect the [5-13C]glutamate resonance in our experimentswhichwas
ascribed to the close proximity of the large [1-13C]acetate resonance
(the glutamate resonance is expected 0.1–0.2 ppm upﬁeld from the ac-
etate resonance). It must be borne in mind that it should be possible to
further increase the sensitivity of these experiments by enhancing the
initial polarization level of the 13C nucleus through the improvement
of the acetate substrate preparation [58,59].
The myocardial VTCA was estimated using the three different kinetic
models. Two of the proposed models do not directly take into account
thedynamics of the injected substrate and only dependon the evolution
of the acetylcarnitine and citrate signals, which originate from the tissue
compartment. By excluding the time evolution of the acetate signal, a
substantial part of which originates from the vascular compartment, it
was observed that the estimation of the metabolic parameters is affect-
ed (Table 2). Additionally, it was observed that the parameters deter-
mining the acetate signal evolution did not correlate with the kinetic
parameters related to acetylcarnitine and citrate 13C labeling (Fig. S1),
showing that the acetylcarnitine and citrate signal evolution are inde-
pendent of the bolus dynamics of the injected substrate. The 13C labeling
kinetics of [1-13C]acetylcarnitine was however found to be dependent
on the dose of injected hyperpolarized [1-13C]acetate. This dose depen-
dence is consistent with the role of mitochondrial carnitine acetyltrans-
ferase and acetylcarnitine as buffer system for intramitochondrial
acetylCoA. A similar dose dependence was reported in a previous
study in rat skeletal muscle from which the in vivo ACS Michaelis–
Menten parameters could be derived [35]. Michaelis–Menten parame-
ters were not determined in the present work because of the large
contribution of the ventricular compartment to the acetate signal. A
ratiometric analysis of hyperpolarized acetate metabolism was also
performed in the earlier skeletal muscle study, showing that meta-
bolic rates and ﬂuxes can be estimated without the need for mathe-
matical modeling [35]. A linear relationship between kACS and the
acetylcarnitine-to-acetate ratio was indeed observed, leading to a
simple mathematical deﬁnition to convert the acetylcarnitine-to-
acetate ratio to a kinetic rate constant kACS. In the present study, a linear
relationship was also observed, but only between the acetylcarnitine-
to-acetate ratio and kACS. This suggests that a ratiometric approach is ap-
propriate to analyze the ACS activity. However, no correlation between
the evolution of the citrate signal and the acetylcarnitine or acetate sig-
nal could be detected. A possible explanation for this absence of corre-
lation might be related to the potential increase of the acetylCoA pool
resulting from the large amount of injected acetate that could lead to
the sequestration of CoA. Since no acetylCoA signal was detected and
because of the rate limiting role of ACS previously observed [35], it is
rather hypothesized that the discrepancy is due to the fact that it is
not possible to separate the acetylcarnitine signals originating from
the cytosolic and mitochondrial compartments, which are very likely
to have a different 13C labeling dynamics. Regardless of the reason be-
hind this absence of correlation, it indicates that it is not possible to
use a ratiometric approach to derive VTCA and that the kinetics of the
acetylcarnitine signal cannot be used as a marker of mitochondrial oxi-
dative metabolism. Note that the use of adiabatic excitation pulses
provided identical excitation and detection for all metabolites and
enabled observation of true ratios independent of their location in
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encoded spatial localization were used for data acquisition, potential
signal contamination from the superﬁcial muscle was excluded due
to difference in kinetics of acetylcarnitine and absence of 13C citrate
in an earlier study performed in skeletal muscle [35], as well as the
absence of the 13C acetylcarnitine resonance in the chest muscle in
13C images of acetylcarnitine [52]. It has to be noted that if there
would be contamination from surrounding muscle tissue, this
would only attribute to the 13C acetylcarnitine signal. Since the esti-
mation of VTCA is independent on the kinetics of 13C acetylcarnitine
using model 3, which is only dependent on the 13C citrate signal evo-
lution, model 3 is most robust for 13C localization or compartmenta-
tion uncertainties.
In 13C MRS studies, information about endogenous pool sizes is nec-
essary to derive quantitative metabolic ﬂuxes. These pool sizes can
change as a result of diseases, altered nutritional states such as fasting
[60], or substrate injection, especially during the long infusion times
necessary to perform thermally-polarized 13C MRS experiments. In
the present hyperpolarized 13C MRS study, downstream metabolic
pool sizes were most likely not notably modiﬁed within the 30–
60 s following the injection of the acetate bolus, i.e., within the
time window of the measurements. This is again supported by the
rate limiting role of ACS on acetate metabolism [35]. Based on this
hypothesis and using the previously determined citrate concentra-
tion (1.48 μmol/g dry weight) [49], VTCA was estimated to be 6.7 ±
1.7 μmol · g−1 · min−1 (dry weight). Although this value is compa-
rable to previously published ﬂuxes determined from 13C MRS or ra-
dioactive labeled carbon experiments performed during a long
acetate infusion in perfused heart or in vivo and typically leading to
VTCA comprised between 7.4 and 14 μmol · g−1 · min−1 (dry weight)
[3,15,16,61], the values estimated in the present work correspond to the
lower end of the range. This might at ﬁrst appear counter-intuitive since
the RPP recorded in this in vivo study (~50 k mm Hg min−1; Table 1)
was signiﬁcantly larger than the reported RPP in earlier studies (~20 k
to 30 k mm Hg min−1) [3,15], and a larger VTCA is usually expected
with increased RPP.
A limitation of the present work is the absence of comparison with a
gold standard method such as the measurement of oxygen consump-
tion rate (MVO2). Although reporting similar VTCA, the obtained MVO2
varied between 16 (in vivo [15]) and 29 to 31 μmol · g−1 · min−1
(dry weight) (in perfused heart [3,16,61]), suggesting a more efﬁcient
energy conversion in vivo. Future studies should incorporate such a
comparison to validate the estimated values of VTCA obtained in the
present study.
It is hypothesized that the low VTCA measured in the present study
could be a consequence of the drastically shorter time of hyperpolarized
13C MRS experiments as compared to thermally-polarized 13C MRS or
radioactively labeled carbon experiments. This might imply that varia-
tions in VTCA resulting frommyocardial conditioning to the infused sub-
strate can be neglected, which highlight the potential beneﬁt of the
short time frame of hyperpolarized 13C experiments for cardiac studies.
5. Conclusion
We showed that it is possible to estimate myocardial VTCA in vivo
through the time-resolved 13C MRS measurement of [5-13C]citrate
following the injection of hyperpolarized [1-13C]acetate. VTCA and
the dynamics of 13C citrate labeling were independent on the
amount of injected substrate and did not correlate with the dynam-
ics of 13C acetylcarnitine labeling. The resulting VTCA value is similar
to values previously determined indirectly through the several-hour
measurements of glutamate 13C labeling, although the results ob-
tained through hyperpolarized 13C MRS might be more accurate be-
cause it provides an almost instantaneous readout after the injection
of the non-physiological dose of acetate. We expect that dynamic 13C
MRS coupled to the injection of hyperpolarized [1-13C]acetate canenable the measurement of metabolic changes during impaired
heart function.
Fatty acid metabolism could ideally be probed with longer-chain
substrates such as palmitate in order to provide information on the dy-
namics of beta oxidation. However, although in vivo butyrate and
octanoate metabolismwasmeasured in the rat heart by hyperpolarized
13C MR [32,37,62], their shorter T1 as compared to acetate limits even
more the sensitivity and therefore the possibility for translation to
human applications.
The clinical potential of hyperpolarized MR is widely recognized,
in particular in cancer research [63], and the ﬁrst trial in patients
using [1-13C]pyruvate demonstrated that this technology can pro-
vide unique metabolic information for diagnostic purposes [64].
The foreseen applications in cardiac imaging and their expected im-
pact in cardiology have been recently discussed [65–67]. Although
hyperpolarized [1-13C]acetate would be a unique probe to determine
VTCA in humans, it would require the use of a high-ﬁeld MR scanner
and high-order shim coils to resolve the [5-13C]citrate peak. Consid-
ering the rather rapid spread of 7 T human MRI technology, it is nev-
ertheless not excluded that the method herein proposed could be
one day translated for human applications.
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